Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer

Abstract This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxaliplatin) as a first-line treatment for unresectable metastatic colorectal...

Full description

Bibliographic Details
Main Authors: Miao-Zhen Qiu, Yuxian Bai, Jufeng Wang, Kangsheng Gu, Mudan Yang, Yifu He, Cheng Yi, Yongdong Jin, Bo Liu, Feng Wang, Yu-kun Chen, Wei Dai, Yingyi Jiang, Chuanpei Huang, Rui-Hua Xu, Hui-Yan Luo
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02063-0

Internet

https://doi.org/10.1038/s41392-024-02063-0

Similar Items